The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.
 
Ryan C Lynch
Consulting or Advisory Role - MorphoSys
Research Funding - Bayer; Cyteir; Genentech; Incyte; RAPT Therapeutics; Seagen; TG Therapeutics
 
Christina Poh
Honoraria - Acrotech Biopharma
Consulting or Advisory Role - MorphoSys
Research Funding - Incyte
 
Chaitra Shankar Ujjani
Honoraria - Abbvie; AstraZeneca; BeiGene; Genentech; incyte; Janssen; Kite/Gilead; Lilly; MorphoSys; Pharmacyclics; TG Therapeutics
Consulting or Advisory Role - AstraZeneca; Atara Biotherapeutics; Epizyme
Research Funding - Abbvie (Inst); Adaptive Biotechnologies; AstraZeneca/MedImmune; Kite, a Gilead company; Lilly; Pharmacyclics (Inst)
 
Edus H. Warren
Stock and Other Ownership Interests - Abbvie
 
Stephen Douglas Smith
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Coherus Biosciences (I); Incyte; Karyopharm Therapeutics; Kite, a Gilead company; Takeda
Research Funding - Acerta Pharma/AstraZeneca (Inst); Ayala Pharmaceuticals (I); Bayer (Inst); BeiGene; Bristol-Myers Squibb (I); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (I); Incyte (Inst); Merck (Inst); Portola Pharmaceuticals (Inst)
 
Mazyar Shadman
Consulting or Advisory Role - Abbvie; Adaptimmune; Adaptive Biotechnologies; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Cellectar; Epizyme; Fate therapeutics; Genentech; Innate Pharma; Kite, a Gilead company; Lilly; MEI Pharma; MorphoSys; MustangBio; Pharmacyclics; Regeneron; Sound Biologics; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Genentech (Inst); Merck (Inst); MustangBio (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Karolyn Morris
No Relationships to Disclose
 
Heather Rasmussen
No Relationships to Disclose
 
Susan Ottemiller
No Relationships to Disclose
 
Megan Shelby
No Relationships to Disclose
 
Sarith Keo
No Relationships to Disclose
 
Jake J. Chabon
Employment - Foresight Diagnostics
Stock and Other Ownership Interests - Foresight Diagnostics
 
Ted Gooley
Consulting or Advisory Role - Kiadis Pharma; Pharmacyclics; Regimmune
 
Jenna M. Voutsinas
No Relationships to Disclose
 
Ajay K. Gopal
Honoraria - Actinium Pharmaceuticals; ADC Therapeutics; Amgen; Cellectar; Epizyme; Gilead Sciences; I-mab; Janssen Oncology; Kite/Gilead; Merck; morphosys; nurix; Pfizer; Seagen; Takeda; TG Therapeutics
Consulting or Advisory Role - Cellectar; Gilead Sciences; I-Mab; Incyte; Janssen Oncology; Kite/Gilead; Millennium; morphosys; nurix; Pfizer; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); I-Mab (Inst); IgM (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst)